Quote:

---

Ohm, about PD-L1 inhibitors, doesn’t Leronlimab do more then this.

---

Leronlimab elicits an NKT cell response, Inhibits angiogenesis, shuts down cancer reappearing through collagen downregulation, Stops the recruitment of Tregs to tumor sites (Tregs promote tumor immunity), inhibits tumor cell dna repair, inhibits IL-13 a tumor protectant, downregulates IL-4 (IL-4 promotes tumor immunity), upregulates IFN-gamma promoting tumor cell death, downregulates PD-1/PD-L1, polarization of macrophages , downregulates calcium channel signaling, blocks CCL5 shutting down pathways for CTCs.